SN BioScience’s SNB-101 Gains Orphan Drug Designation from the US FDA for the Treatment of Pancreatic Cancer
Shots:
- SN Bioscience’s SNB-101 has received ODD on Feb 27 from the US FDA for the treatment of pancreatic cancer on the basis of preclinical results. It has previously received the US FDA’s ODD for treating SCLC in Jul 2023
- The preclinical results demonstrated the drug’s efficacy as compared to Abraxane & Onivyde (existing 1L treatments) in animal models for pancreatic cancer
- Additionally, in Nov 2023, the company received approval for SNB-101’s P-II trial in Korea. The approval for P-I study has been received in the US (NCT04640480) & Korea while the INDs for P-II studies are expected in H2’24 across the US and the EU
Ref: BioLineRx | Image: BioLineRx
Related News:- BioLineRx Reports First Patient Dosing with Motixafortide in P-II Study for the Treatment of Pancreatic Cancer (PDAC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
